Key Points:
TPM® Oxymorphone Patch pre-IND, FDA face-to-face meeting confirmed for December ‘18.
Injectable candidates continue to progress – development candidates on track for 2018 Tox
Multiple companies undertaking due diligence on Animal Health Business.
Strong Vital ET sales on forecast for 2018
Independent research coverage rates POH a ‘Buy’ with target 8-9 cents share price
Mylan Arbitration Outcome: still to come
..for those interested in more than a quick buck, look no further!
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.86M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9600 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 9599 | 1 |
View Market Depth
| Last trade - 09.45am 30/07/2025 (20 minute delay) ? |
| AVE (ASX) Chart |
Day chart unavailable